Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (2020 - 2025)

Silence Therapeutics' Shares Outstanding history spans 5 years, with the latest figure at $141.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 200.06% year-over-year to $141.7 million; the TTM value through Dec 2025 reached $141.7 million, up 200.06%, while the annual FY2025 figure was $141.7 million, 0.02% changed from the prior year.
  • Shares Outstanding for Q4 2025 was $47.2 million at Silence Therapeutics, roughly flat from $47.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $147.5 million in Q4 2023 and bottomed at $47.2 million in Q4 2024.
  • The 5-year median for Shares Outstanding is $139.7 million (2024), against an average of $112.9 million.
  • The largest annual shift saw Shares Outstanding plummeted 67.98% in 2024 before it surged 200.06% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $121.0 million in 2021, then rose by 4.48% to $126.5 million in 2022, then rose by 16.65% to $147.5 million in 2023, then tumbled by 67.98% to $47.2 million in 2024, then soared by 200.06% to $141.7 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Shares Outstanding are $141.7 million (Q4 2025), $47.2 million (Q3 2025), and $141.7 million (Q2 2025).